Meta-Analysis: Rosuvastatin May Be Superior for Plaque Regression

This article originally appeared here.
Share this content:
Meta-Analysis: Rosuvastatin May Be Superior for Plaque Regression
Meta-Analysis: Rosuvastatin May Be Superior for Plaque Regression

WEDNESDAY, Nov. 18, 2015 (HealthDay News) -- Rosuvastatin appears to be more effective than atorvastatin for regression of coronary atherosclerotic plaques, according to a meta-analysis published in the Nov. 15 issue of The American Journal of Cardiology.

Cheng Qian, M.D., from Zhongnan Hospital of Wuhan University in China, and colleagues conducted a meta-analysis to provide evidence for proper statin selection for the reversion of coronary atherosclerotic plaques. Five randomized trials that met predefined inclusion criteria were analyzed, with a total of 1,556 participants, of whom 772 were in the rosuvastatin group and 784 in the atorvastatin group.

In all included trials, the dose ratios of rosuvastatin versus atorvastatin were 1:2. The researchers found that rosuvastatin administration further reduced the total atheroma volume (P = 0.004) and percent atheroma volume (P = 0.03), compared with atorvastatin, and correlated with more improvement in lumen volume (P = 0.046). There was no difference in the comparative regression of plaques across subgroups.

"In conclusion, rosuvastatin is superior to atorvastatin in the reversion of coronary atherosclerotic plaques," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths